$Altimeter Growth Corp (AGC.US)$
Southeast Asia's ride-hailing giant Grab set to merge with U.S. firm Altimeter Growth. According to the Forbes, The transaction—which will be the world’s largest SPAC deal—will give Grab a valuation of $40 billion.
SoftBank-backed Grab, founded in 2012, is a Southeast Asia's leading superapp based on GMV in 2020 in each of food deliveries, mobility and the e-wallets segment of financial services, according to Euromonitor.
According to Form F-4, an extraordinary general meeting will be held on November 30, 2021 to consider and vote upon the business combination proposal.
Grab generated revenue of $78 million and $396 million in the six months ended June 30, 2020 and June 30, 2021, respectively, representing a year-over-year growth rate of 406%. Its revenue was $(845) million and $469 million in 2019 and 2020, respectively, representing a year-over-year growth rate of 155%. According to Grab's final Form F-4, its revenue growth in 2020 and the six months ended June 30, 2021 was driven by an increase in GMV. Its GMV was $5.9 billion and $7.5 billion in the six months ended June 30, 2020 and 2021, representing a YoY growth rate of 28%.
Upon completion of its merger, the SoftBank-backed company will trade on the Nasdaq under ticker symbol GRAB. Grab will receive about $4.5 billion in cash, which includes $4 billion in a private investment in public equity arrangement.
The SEC gave the green light to the proposed merger between AGC and Grab. With an Extraordinary General Meeting of AGC shareholders to approve the merger coming up on Tuesday (Nov 30)
AGC SPAC: Sponsored by institution with notable VC investmentsAltimeter Growth Corp.(AGC.US) is a newly formed blank check company, an affiliate of Altimeter Capital Management which is a technology-focused investment firm. Altimeter Capital has a proven track record of successfully investing in leading technology companies in both the private and public markets. According to its Form F-4,some of its prior investments include Expedia, Zillow, Facebook, Uber, AirBnB, ByteDance, AppDynamics, MongoDB, Okta, Twilio, Unity, and Snowflake.
Through the business combination, Grab could leverage Altimeter Capital’s investment team's capabilities, relationships, network, and deal pipeline to support it in the identification and diligence of potential targets.
This couldn’t come at a more opportune time for Grab. Enthusiasm for SPAC mergers is recovering at the moment, and tech stocks in particular remain hot.
While some investors might still be wary of highly valued growth stocks, Grab presents a good option for those seeking exposure to Southeast Asia tech markets. Investors seeking alternatives to mainland Chinese stocks amid the ongoing tech clampdown there might also look towards Grab favourably.
The twentyfold stock price appreciation of e-commerce giant Sea Limited since its IPO in 2017, has also affirmed the potential of the under-represented Southeast Asia market. Grab is the next big tech unicorn from this region, and it might benefit from these supportive trends.
https://www.moomoo.com/community/feed/107359430246405?lang_code=2
https://www.channelnewsasia.com/commentary/grab-ipo-listing-spac-agc-merger-stock-valuation-sgx-gig-economy-app-tech-2345096?cid=FBcna&fbclid=IwAR0Qj7-sn6aRhfpHF_bJcjTBOhq5Fk-SGUKaxfURDEztjPSQEmRbXIR3niU
$Meta Platforms (FB.US)$
$Netflix (NFLX.US)$
$Twitter (Delisted) (TWTR.US)$
$Amazon (AMZN.US)$
$Advanced Micro Devices (AMD.US)$
$NVIDIA (NVDA.US)$
$Tesla (TSLA.US)$
$Sea (SE.US)$
$Futu Holdings Ltd (FUTU.US)$
$Moderna (MRNA.US)$
$Uber Technologies (UBER.US)$
$Salesforce (CRM.US)$
$iSpecimen (ISPC.US)$
Southeast Asia's ride-hailing giant Grab set to merge with U.S. firm Altimeter Growth. According to the Forbes, The transaction—which will be the world’s largest SPAC deal—will give Grab a valuation of $40 billion.
SoftBank-backed Grab, founded in 2012, is a Southeast Asia's leading superapp based on GMV in 2020 in each of food deliveries, mobility and the e-wallets segment of financial services, according to Euromonitor.
According to Form F-4, an extraordinary general meeting will be held on November 30, 2021 to consider and vote upon the business combination proposal.
Grab generated revenue of $78 million and $396 million in the six months ended June 30, 2020 and June 30, 2021, respectively, representing a year-over-year growth rate of 406%. Its revenue was $(845) million and $469 million in 2019 and 2020, respectively, representing a year-over-year growth rate of 155%. According to Grab's final Form F-4, its revenue growth in 2020 and the six months ended June 30, 2021 was driven by an increase in GMV. Its GMV was $5.9 billion and $7.5 billion in the six months ended June 30, 2020 and 2021, representing a YoY growth rate of 28%.
Upon completion of its merger, the SoftBank-backed company will trade on the Nasdaq under ticker symbol GRAB. Grab will receive about $4.5 billion in cash, which includes $4 billion in a private investment in public equity arrangement.
The SEC gave the green light to the proposed merger between AGC and Grab. With an Extraordinary General Meeting of AGC shareholders to approve the merger coming up on Tuesday (Nov 30)
AGC SPAC: Sponsored by institution with notable VC investmentsAltimeter Growth Corp.(AGC.US) is a newly formed blank check company, an affiliate of Altimeter Capital Management which is a technology-focused investment firm. Altimeter Capital has a proven track record of successfully investing in leading technology companies in both the private and public markets. According to its Form F-4,some of its prior investments include Expedia, Zillow, Facebook, Uber, AirBnB, ByteDance, AppDynamics, MongoDB, Okta, Twilio, Unity, and Snowflake.
Through the business combination, Grab could leverage Altimeter Capital’s investment team's capabilities, relationships, network, and deal pipeline to support it in the identification and diligence of potential targets.
This couldn’t come at a more opportune time for Grab. Enthusiasm for SPAC mergers is recovering at the moment, and tech stocks in particular remain hot.
While some investors might still be wary of highly valued growth stocks, Grab presents a good option for those seeking exposure to Southeast Asia tech markets. Investors seeking alternatives to mainland Chinese stocks amid the ongoing tech clampdown there might also look towards Grab favourably.
The twentyfold stock price appreciation of e-commerce giant Sea Limited since its IPO in 2017, has also affirmed the potential of the under-represented Southeast Asia market. Grab is the next big tech unicorn from this region, and it might benefit from these supportive trends.
https://www.moomoo.com/community/feed/107359430246405?lang_code=2
https://www.channelnewsasia.com/commentary/grab-ipo-listing-spac-agc-merger-stock-valuation-sgx-gig-economy-app-tech-2345096?cid=FBcna&fbclid=IwAR0Qj7-sn6aRhfpHF_bJcjTBOhq5Fk-SGUKaxfURDEztjPSQEmRbXIR3niU
$Meta Platforms (FB.US)$
$Netflix (NFLX.US)$
$Twitter (Delisted) (TWTR.US)$
$Amazon (AMZN.US)$
$Advanced Micro Devices (AMD.US)$
$NVIDIA (NVDA.US)$
$Tesla (TSLA.US)$
$Sea (SE.US)$
$Futu Holdings Ltd (FUTU.US)$
$Moderna (MRNA.US)$
$Uber Technologies (UBER.US)$
$Salesforce (CRM.US)$
$iSpecimen (ISPC.US)$
38
4
Maribavir will be the first and only treatment indicated for adults in this patient population, expected net profit value at amazing $1.118B
$Takeda Pharmaceutical (TAK.US)$
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
$Pasithea Therapeutics (KTTA.US)$
$Petros Pharmaceuticals (PTPI.US)$
$iSpecimen (ISPC.US)$
$Longeveron (LGVN.US)$
$Takeda Pharmaceutical (TAK.US)$
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
$Pasithea Therapeutics (KTTA.US)$
$Petros Pharmaceuticals (PTPI.US)$
$iSpecimen (ISPC.US)$
$Longeveron (LGVN.US)$
6
$Sono Group (SEV.US)$
Only 1m float of stock available, HODL for high price Sion A spacious electric car with a range of up to 305 kilometers that charges itself through the power of the sun.
Takes 30mins to charge vehicle to 80% and the rest could just charge on the go with solar power!
Sono reported more than 14,000 reservations with advance payments, resulting in total net cash inflows of 38.8 million euros ($45.16 million) from its customers by August-end, up from total net cash inflows of 37.9 million euros at the end of June. These reservations correspond to a net sales volume of about 300 million euros.
It plans to license and sell its solar technology to manufacturers of buses, trucks, camper vans, trains and even boats, Sono said. https://sonomotors.com/en/solar-integration/
In addition, their Cybertruck has more than 1 million preorders, according to a report from Electrek
Learn more about Sonomotors in their video https://www.youtube.com/watch?v=9MlQMG5S-_o
$Sono Group (SEV.US)$ $iSpecimen (ISPC.US)$
$Tesla (TSLA.US)$
$Pioneer Power Solutions (PPSI.US)$
$ChargePoint (CHPT.US)$
$Rivian Automotive (RIVN.US)$
$Lucid Group (LCID.US)$
$Canoo (GOEV.US)$
$Gores Guggenheim (GGPI.US)$
$Qualigen Therapeutics (QLGN.US)$
$Longeveron (LGVN.US)$
$Petros Pharmaceuticals (PTPI.US)$
$Aadi Biosciences (AADI.US)$
$iSpecimen (ISPC.US)$
$RLX Technology (RLX.US)$
$XPeng (XPEV.US)$
Only 1m float of stock available, HODL for high price Sion A spacious electric car with a range of up to 305 kilometers that charges itself through the power of the sun.
Takes 30mins to charge vehicle to 80% and the rest could just charge on the go with solar power!
Sono reported more than 14,000 reservations with advance payments, resulting in total net cash inflows of 38.8 million euros ($45.16 million) from its customers by August-end, up from total net cash inflows of 37.9 million euros at the end of June. These reservations correspond to a net sales volume of about 300 million euros.
It plans to license and sell its solar technology to manufacturers of buses, trucks, camper vans, trains and even boats, Sono said. https://sonomotors.com/en/solar-integration/
In addition, their Cybertruck has more than 1 million preorders, according to a report from Electrek
Learn more about Sonomotors in their video https://www.youtube.com/watch?v=9MlQMG5S-_o
$Sono Group (SEV.US)$ $iSpecimen (ISPC.US)$
$Tesla (TSLA.US)$
$Pioneer Power Solutions (PPSI.US)$
$ChargePoint (CHPT.US)$
$Rivian Automotive (RIVN.US)$
$Lucid Group (LCID.US)$
$Canoo (GOEV.US)$
$Gores Guggenheim (GGPI.US)$
$Qualigen Therapeutics (QLGN.US)$
$Longeveron (LGVN.US)$
$Petros Pharmaceuticals (PTPI.US)$
$Aadi Biosciences (AADI.US)$
$iSpecimen (ISPC.US)$
$RLX Technology (RLX.US)$
$XPeng (XPEV.US)$
32
1
$Takeda Pharmaceutical (TAK.US)$
If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population
The FDA has placed Takeda's New Drug Application for maribavir under Priority Review, and this vote of confidence from the AMDAC will be taken into account when the regulator makes its final decision. The NDA submission is based on the Phase III study. The AMDAC also collected insights and responses from advocates, patients, and healthcare providers in a public forum.
The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee (AMDAC) has unanimously voted on the use of Takeda Pharmaceutical Company's maribavir to treat different types of refractory cytomegalovirus (CMV) infection.
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
https://www.biospace.com/article/candidate-cmv-infection-therapy-maribavir-gets-nod-from-key-fda-advisory-committee/
https://www.businesswire.com/news/home/20211007006064/en/FDA-Advisory-Committee-Recommends-Use-of-Investigational-Drug-Maribavir-TAK-620-to-Treat-Post-Transplant-Recipients-with-Cytomegalovirus-CMV-Infection-and-Disease-Refractory-to-Treatment-With-or-Without-Resistance
In addition, there was a big insider buy
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.
“At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value,” said Costa Saroukos, director and Chief Financial Officer of Takeda. “We expect that this share buyback of up to 100B yen will not impact our deleveraging plans, and that we will remain firmly on track to deliver on our target for 2x (‘low twos’) net debt to Adjusted EBITDA by the end of FY23. We are also maintaining our existing dividend policy and updating our capital allocation policy to allow for share buybacks in the future when appropriate. This underscores our business’ strong cash generation ability, our confidence in our fundamental growth driven by the 14 global brands, and our belief that the R&D strategy with ~40 new molecular entities in the pipeline, will deliver for the long term.”
This buyback of shares will be funded by Takeda’s operating cash flow driven by growth in our 14 global brands and working capital improvements.
https://www.takeda.com/newsroom/newsreleases/2021/takeda-announces-acquisition-of-own-shares/
$Longeveron (LGVN.US)$
$RenovoRx (RNXT.US)$
$Novavax (NVAX.US)$
$ChemoCentryx (CCXI.US)$
$Pfizer (PFE.US)$
$Futu Holdings Ltd (FUTU.US)$
$Moderna (MRNA.US)$
$BioNTech (BNTX.US)$
$CorMedix (CRMD.US)$
$Amgen (AMGN.US)$
$Sanofi (SNY.US)$
$Bristol-Myers Squibb (BMY.US)$
$MERCK KGAA SPON ADR EACH REPR 0.2 ORD SHS (MKKGY.US)$
$Johnson & Johnson (JNJ.US)$
$AbbVie (ABBV.US)$
$Novartis AG (NVS.US)$
$ROCHE HOLDING AG (RHHBY.US)$
$iSpecimen (ISPC.US)$
$Petros Pharmaceuticals (PTPI.US)$
$Aadi Biosciences (AADI.US)$
$Pasithea Therapeutics (KTTA.US)$
$Fennec Pharmaceuticals (FENC.US)$
If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population
The FDA has placed Takeda's New Drug Application for maribavir under Priority Review, and this vote of confidence from the AMDAC will be taken into account when the regulator makes its final decision. The NDA submission is based on the Phase III study. The AMDAC also collected insights and responses from advocates, patients, and healthcare providers in a public forum.
The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee (AMDAC) has unanimously voted on the use of Takeda Pharmaceutical Company's maribavir to treat different types of refractory cytomegalovirus (CMV) infection.
CMV is a beta herpes virus that commonly affects individuals who have compromised immune systems. Out of the approximately 200,000 adult transplants per year worldwide, CMV is one of the most common viral infections. It has an estimated incidence rate of between 16% and 56% in solid organ transplant recipients and 30% to 70% percent in hematopoietic stem cell transplant patients.
https://www.biospace.com/article/candidate-cmv-infection-therapy-maribavir-gets-nod-from-key-fda-advisory-committee/
https://www.businesswire.com/news/home/20211007006064/en/FDA-Advisory-Committee-Recommends-Use-of-Investigational-Drug-Maribavir-TAK-620-to-Treat-Post-Transplant-Recipients-with-Cytomegalovirus-CMV-Infection-and-Disease-Refractory-to-Treatment-With-or-Without-Resistance
In addition, there was a big insider buy
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below.
“At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value,” said Costa Saroukos, director and Chief Financial Officer of Takeda. “We expect that this share buyback of up to 100B yen will not impact our deleveraging plans, and that we will remain firmly on track to deliver on our target for 2x (‘low twos’) net debt to Adjusted EBITDA by the end of FY23. We are also maintaining our existing dividend policy and updating our capital allocation policy to allow for share buybacks in the future when appropriate. This underscores our business’ strong cash generation ability, our confidence in our fundamental growth driven by the 14 global brands, and our belief that the R&D strategy with ~40 new molecular entities in the pipeline, will deliver for the long term.”
This buyback of shares will be funded by Takeda’s operating cash flow driven by growth in our 14 global brands and working capital improvements.
https://www.takeda.com/newsroom/newsreleases/2021/takeda-announces-acquisition-of-own-shares/
$Longeveron (LGVN.US)$
$RenovoRx (RNXT.US)$
$Novavax (NVAX.US)$
$ChemoCentryx (CCXI.US)$
$Pfizer (PFE.US)$
$Futu Holdings Ltd (FUTU.US)$
$Moderna (MRNA.US)$
$BioNTech (BNTX.US)$
$CorMedix (CRMD.US)$
$Amgen (AMGN.US)$
$Sanofi (SNY.US)$
$Bristol-Myers Squibb (BMY.US)$
$MERCK KGAA SPON ADR EACH REPR 0.2 ORD SHS (MKKGY.US)$
$Johnson & Johnson (JNJ.US)$
$AbbVie (ABBV.US)$
$Novartis AG (NVS.US)$
$ROCHE HOLDING AG (RHHBY.US)$
$iSpecimen (ISPC.US)$
$Petros Pharmaceuticals (PTPI.US)$
$Aadi Biosciences (AADI.US)$
$Pasithea Therapeutics (KTTA.US)$
$Fennec Pharmaceuticals (FENC.US)$
81
4
$Sono Group (SEV.US)$
Only 10m float of stock available, HODL for high price. Combination of EV and solar panel in one. Market cap is way lower as compared to competitors
Sion
A spacious electric car with a range of up to 305 kilometers that charges itself through the power of the sun.
Takes 30mins to charge vehicle to 80% and the rest could just charge on the go with solar power!
Sono reported more than 14,000 reservations with advance payments, resulting in total net cash inflows of 38.8 million euros ($45.16 million) from its customers by August-end, up from total net cash inflows of 37.9 million euros at the end of June. These reservations correspond to a net sales volume of about 300 million euros.
It plans to license and sell its solar technology to manufacturers of buses, trucks, camper vans, trains and even boats, Sono said. https://sonomotors.com/en/solar-integration/
In addition, their Cybertruck has more than 1 million preorders, according to a report from Electrek
Learn more about Sonomotors in their video https://www.youtube.com/watch?v=9MlQMG5S-_o
$Sono Group (SEV.US)$
$Pioneer Power Solutions (PPSI.US)$
$Longeveron (LGVN.US)$
$Phunware (PHUN.US)$
$Alibaba (BABA.US)$
$Rivian Automotive (RIVN.US)$
$Tesla (TSLA.US)$
$Lucid Group (LCID.US)$
$Canoo (GOEV.US)$
$Gores Guggenheim (GGPI.US)$
$Futu Holdings Ltd (FUTU.US)$
$Apple (AAPL.US)$
$Biora Therapeutics (PROG.US)$
$NVIDIA (NVDA.US)$
Only 10m float of stock available, HODL for high price. Combination of EV and solar panel in one. Market cap is way lower as compared to competitors
Sion
A spacious electric car with a range of up to 305 kilometers that charges itself through the power of the sun.
Takes 30mins to charge vehicle to 80% and the rest could just charge on the go with solar power!
Sono reported more than 14,000 reservations with advance payments, resulting in total net cash inflows of 38.8 million euros ($45.16 million) from its customers by August-end, up from total net cash inflows of 37.9 million euros at the end of June. These reservations correspond to a net sales volume of about 300 million euros.
It plans to license and sell its solar technology to manufacturers of buses, trucks, camper vans, trains and even boats, Sono said. https://sonomotors.com/en/solar-integration/
In addition, their Cybertruck has more than 1 million preorders, according to a report from Electrek
Learn more about Sonomotors in their video https://www.youtube.com/watch?v=9MlQMG5S-_o
$Sono Group (SEV.US)$
$Pioneer Power Solutions (PPSI.US)$
$Longeveron (LGVN.US)$
$Phunware (PHUN.US)$
$Alibaba (BABA.US)$
$Rivian Automotive (RIVN.US)$
$Tesla (TSLA.US)$
$Lucid Group (LCID.US)$
$Canoo (GOEV.US)$
$Gores Guggenheim (GGPI.US)$
$Futu Holdings Ltd (FUTU.US)$
$Apple (AAPL.US)$
$Biora Therapeutics (PROG.US)$
$NVIDIA (NVDA.US)$
28
2
$Sono Group (SEV.US)$
As of November 5, 2021, the company had over 16,000 reservations for future deliveries totaling approximately $43.9 million in deposits received.
https://sonomotors.com
As of November 5, 2021, the company had over 16,000 reservations for future deliveries totaling approximately $43.9 million in deposits received.
https://sonomotors.com
14
$Cenntro Electric (NAKD.US)$
11/08/2021 (MT Newswires) -- Naked Brand Group (NAKD) and Cenntro Automotive Group, Inc. said Monday that they have entered into a definitive agreement under which Naked will acquire the outstanding stock in three entities comprising Cenntro Automotive Group in a stock for stock acquisition agreement According to a media release, Cenntro is a commercial EV technology company with advanced market-validated commercial vehicles and autonomous driving technologies.Upon completion of the transaction, the company expects to change its name to Cenntro Automotive Group and retain its Nasdaq listing and ticker symbol "NAKD".The transaction is expected to close by the year-end of 2021.
$Rivian Automotive (RIVN.US)$
$RenovoRx (RNXT.US)$
$Tesla (TSLA.US)$
$NIO Inc (NIO.US)$
$Lucid Group (LCID.US)$
$EVgo Inc (EVGO.US)$
$Pioneer Power Solutions (PPSI.US)$
11/08/2021 (MT Newswires) -- Naked Brand Group (NAKD) and Cenntro Automotive Group, Inc. said Monday that they have entered into a definitive agreement under which Naked will acquire the outstanding stock in three entities comprising Cenntro Automotive Group in a stock for stock acquisition agreement According to a media release, Cenntro is a commercial EV technology company with advanced market-validated commercial vehicles and autonomous driving technologies.Upon completion of the transaction, the company expects to change its name to Cenntro Automotive Group and retain its Nasdaq listing and ticker symbol "NAKD".The transaction is expected to close by the year-end of 2021.
$Rivian Automotive (RIVN.US)$
$RenovoRx (RNXT.US)$
$Tesla (TSLA.US)$
$NIO Inc (NIO.US)$
$Lucid Group (LCID.US)$
$EVgo Inc (EVGO.US)$
$Pioneer Power Solutions (PPSI.US)$
10
1
$Phunware (PHUN.US)$
https://www.globenewswire.com/news-release/2021/11/05/2328529/0/en/Phunware-Acquires-Additional-Bitcoin.html
The company said it bought 100 bitcoin at an average price of $62,030 per bitcoin, including fees and expenses. Meanwhile, continuous bitcoin futures were up 0.7% at $61.805, according to FactSet data. Phunware said as of Nov. 4 it owned about 127 bitcoin, which were acquired for $7.75 million at an average price of $61,238.
https://www.globenewswire.com/news-release/2021/11/05/2328529/0/en/Phunware-Acquires-Additional-Bitcoin.html
The company said it bought 100 bitcoin at an average price of $62,030 per bitcoin, including fees and expenses. Meanwhile, continuous bitcoin futures were up 0.7% at $61.805, according to FactSet data. Phunware said as of Nov. 4 it owned about 127 bitcoin, which were acquired for $7.75 million at an average price of $61,238.
1
$Ocugen (OCGN.US)$
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Ocugen will issue a pre-market earnings announcement on the same day. Investors are invited to participate on the call using the following details:Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international)Conference ID: 8198297Webcast: Available in the “Investors” section of the Ocugen website and archived for approximately 45 days following the call
https://ir.ocugen.com/news-releases/news-release-details/ocugen-host-conference-call-tuesday-november-9-830-am-et-discuss
$Moderna (MRNA.US)$
$Pfizer (PFE.US)$
$BioNTech (BNTX.US)$
$Biora Therapeutics (PROG.US)$
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Ocugen will issue a pre-market earnings announcement on the same day. Investors are invited to participate on the call using the following details:Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international)Conference ID: 8198297Webcast: Available in the “Investors” section of the Ocugen website and archived for approximately 45 days following the call
https://ir.ocugen.com/news-releases/news-release-details/ocugen-host-conference-call-tuesday-november-9-830-am-et-discuss
$Moderna (MRNA.US)$
$Pfizer (PFE.US)$
$BioNTech (BNTX.US)$
$Biora Therapeutics (PROG.US)$
11
7
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjYiIGhlaWdodD0iMjYiIHZpZXdCb3g9IjAgMCAyNiAyNiIgZmlsbD0ibm9uZSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMi45OTk5IDAuMzI1NDM5QzYuMDQxMTEgMC4zMjU0MzkgMC4zOTk5MDIgNS45NjY2NSAwLjM5OTkwMiAxMi45MjU0QzAuMzk5OTAyIDE5Ljg4NDIgNi4wNDExMSAyNS41MjU0IDEyLjk5OTkgMjUuNTI1NFYyMi43MjU0QzcuNTg3NTEgMjIuNzI1NCAzLjE5OTkgMTguMzM3OCAzLjE5OTkgMTIuOTI1NEMzLjE5OTkgNy41MTMwNSA3LjU4NzUxIDMuMTI1NDQgMTIuOTk5OSAzLjEyNTQ0VjAuMzI1NDM5WiIgZmlsbD0idXJsKCNwYWludDBfbGluZWFyXzIyMDBfNDg2NikiLz4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMyAyNS41MjU0QzE5Ljk1ODggMjUuNTI1NCAyNS42IDE5Ljg4NDIgMjUuNiAxMi45MjU0QzI1LjYgNS45NjY2NSAxOS45NTg4IDAuMzI1NDQgMTMgMC4zMjU0MzlWMy4xMjU0NEMxOC40MTI0IDMuMTI1NDQgMjIuOCA3LjUxMzA1IDIyLjggMTIuOTI1NEMyMi44IDE4LjMzNzggMTguNDEyNCAyMi43MjU0IDEzIDIyLjcyNTRWMjUuNTI1NFoiIGZpbGw9InVybCgjcGFpbnQxX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxjaXJjbGUgY3g9IjEzLjAwMDEiIGN5PSIyNC4xMjUzIiByPSIxLjQiIGZpbGw9InVybCgjcGFpbnQyX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxkZWZzPgo8bGluZWFyR3JhZGllbnQgaWQ9InBhaW50MF9saW5lYXJfMjIwMF80ODY2IiB4MT0iNy4zOTk5IiB5MT0iMjUuNTI1NCIgeDI9IjcuMzk5OSIgeTI9IjIuNDI1NDQiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDFfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjIwIiB5MT0iMjUuNTI1NCIgeDI9IjIwIiB5Mj0iMi40MjU0NCIgZ3JhZGllbnRVbml0cz0idXNlclNwYWNlT25Vc2UiPgo8c3RvcCBzdG9wLWNvbG9yPSIjN0E3QTdBIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDJfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjEzLjAwMDEiIHkxPSIyNC4xMjUzIiB4Mj0iMTQuNDAwMSIgeTI9IjI0LjEyNTMiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIvPgo8c3RvcCBvZmZzZXQ9IjEiIHN0b3AtY29sb3I9IiM3QTdBN0EiIHN0b3Atb3BhY2l0eT0iMCIvPgo8L2xpbmVhckdyYWRpZW50Pgo8L2RlZnM+Cjwvc3ZnPgo=)